
Why the India-UK FTA has spooked medical device manufacturers. Hint: China
New Delhi: India's free trade agreement with the UK is expected to open up a large market for Indian exporters but has left at least one sector flustered. Domestic manufacturers of medical devices fear Chinese-origin products could be routed into India through the UK by exploiting the zero-tariff provisions under the bilateral trade pact.
Apart from creating larger opportunities for Britain's lifesciences sector, the
India-UK FTA
will mean reduced tariffs for medical devices going through the UK's complex supply chains, which Chinese manufacturers can exploit, said industry experts.
While the UK is not a major medtech manufacturing hub, it could serve as a conduit for third-country goods, particularly Chinese products, seeking backdoor access into India under the zero-duty terms, said a member of the Export Promotion Council of Medical Devices (EPCMD), a body set up by the Indian commerce ministry.
'There is a genuine concern that Chinese-origin products could be routed through the UK to exploit the zero-tariff provisions under an India-UK FTA," this person said, requesting anonymity. 'To prevent this, it is critical to enforce strict rules of origin, including a minimum of 55% UK content, excluding labour, packing, and shipping costs."
The Indian government should consider including a 35% value-addition threshold and mandatory documentation to verify the medical devices imported into India and the manufacturing value-chain, this person added.
Another EPCMD member said the India-UK FTA must include 'stringent origin verification protocols and clearly define the legal manufacturer and substantial transformation requirements".
'India should maintain a mechanism for periodic review of product inflows, activate safeguard clauses where dumping or import surges are observed, and exclude sensitive or vulnerable product categories from blanket zero-tariff concessions," this person added, also asking to not be identified. 'These measures will ensure that genuine UK-origin products benefit from the agreement while protecting India's growing and strategic domestic medical devices ecosystem."
India's medical devices sector is valued at $11 billion and expected to grow to $50 billion by 2030, according to the department of pharmaceuticals.
India's medical device exports increased to
₹
1,015.02 crore in 2023-24 from
₹
897.41 crore in the year before, while imports surged to
₹
2,295.37 crore from 1,682.14 crore.
Also read |
India-UK FTA: Can exporters seize the opportunity amid tough competition?
Rajiv Nath, forum coordinator, Association of Indian Medical Device Industry, said the sector had raised its concerns with the department of pharmaceuticals and the department of commerce.
'We needed fast-track regulatory approval based on ICMED-ISO certification to overcome non-tariff measures put in by the UK and to safeguard Indian manufacturers from rerouted products from China,
etc.,
via the UK as purportedly made-in-UK or UK-country-of-origin products," said Nath.
The Indian Certification for Medical Devices (ICMED) is a voluntary quality certification scheme for domestic medical device manufacturers, combining international quality requirements with Indian regulatory standards.
Under the India-UK FTA, several categories of 'industrial goods" will attract zero import or export duties, including medical devices such as surgical instruments, diagnostic equipment, and electro-medical machinery like ECG machines and X-ray systems.
This means that both imports from the UK to India and exports from India to the UK in these segments will enjoy duty-free access.
The Export Promotion Council of Medical Devices has submitted a proposal to the government with suggestions to safeguard the interests of Indian medtech manufacturers. These include implementing robust rules of origin, providing reciprocal benefits to Indian manufacturers, and ensuring that import-export policies support true value-creation and not just assembly or trading.
Also read |
India, EU discuss textile duty relief in exchange for whisky concessions under FTA
Despite the worries over Chinese products sneaking into India, the medical devices council acknowledged the free trade agreement would widen opportunities for Indian exporters.
'Indian medtech companies can now access the UK market at more competitive landed costs, improving chances of success in tenders and bulk procurement by institutions like the NHS (the UK's National Health Service)," said the first council member quoted above.
'Second, the UK's increasing reluctance to rely on Chinese medical imports positions Indian manufacturers as a favourable alternative, especially with zero-duty pricing. Third, easier access to high-value UK contracts may encourage Indian firms to upgrade quality standards and invest in regulatory compliance, spurring sector-wide growth," this person said.
'However, it also opens the door to potentially harmful import practices that could disadvantage genuine Indian manufacturers. A balanced strategy with strict origin rules, domestic incentives, and regulatory support is crucial to ensuring that the FTA strengthens rather than weakens India's medtech sector," the member added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
15 minutes ago
- Time of India
From Chenab bridge to Madrid stage, a tale of languages that travel, unite and sometimes provoke
Languages have the capacity to either fry bacon or stay gentle and pleasant. At times, simple and short words can be potentially more impactful in conveying powerful messages. All these were easily noticed over the last week or so when phrases of two public figures from Tamil Nadu gained traction. In fact, the speed with which their utterances spread was faster than the time taken by Vande Bharat Express to cross the Chenab bridge , an engineering marvel. But there the similarity ends. If actor-politician Kamal Haasan was intending to lay emphasis on some kind of familial relationship between Tamil and Kannada by his remark that 'Kannada was born out of Tamil', he ended up having a 'Thug Life' image in Karnataka and his movie shunted into the sidings. On the other side of the world was a questioner in Spain who was perhaps yearning for quite a bit of thrill when he asked DMK leader Kanimozhi about India's national language, but her reply that 'the national language of India is unity in diversity' must have derailed the enquirer's train of thoughts off its rails. With her riposte, the member of Parliament signalled that she was in Madrid to guard Indian interests against any type of onslaught, including on languages which, like junctions, intersect and influence each other before reaching their respective platforms. Live Events The gist of the two episodes is that, like people, languages travel far and wide and even to space, helping bridge the gulf, just like the Chenab bridge, which became possible only after people from all corners of India joined hands to conquer insurmountable challenges. Just as Indian cinema and Indian Railways have crossed all hurdles, it's hoped that Kashmir to Kanniyakumari track and field will inspire the nation to live in unity and take delight in diversity.


Economic Times
15 minutes ago
- Economic Times
KKR-backed IVI to buy ART Fertility Clinics for $450 million
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.
&w=3840&q=100)

Business Standard
16 minutes ago
- Business Standard
India hunts for rare earth magnet alternatives as China tightens grip
China holds around 50% of the world's rare earth reserves, 70% of extraction capacity, and over 90% of processing capability Puja Das Delhi Listen to This Article India is exploring alternative sources to import rare earth magnets amid ongoing supply disruptions from China, as there are no temporary domestic options available, according to a senior government official. Following the escalating tariffs imposed by US President Donald Trump on China, Beijing enacted export restrictions on seven heavy and medium rare earth elements and magnets on April 4. These include samarium, gadolinium, terbium, dysprosium, lutetium, scandium, and yttrium, which are used in defence, energy, and automotive (auto) technologies. Chinese companies are now required to secure defence licences to export these resources. Despite India assuring that these magnets will only